Featured Case Study
Market Entry Strategy for Novel Psychedelic Therapeutic
Our client, a European-based biopharmaceutical company, was developing innovative psychedelic therapies. Their lead compound showed promise across multiple mental health indications. As they prepared for their Series A funding round, they needed expert guidance on selecting the optimal indication for development and eventual launch in the US market.
Challenge
Our client faced several critical challenges:
- Limited understanding of the complex US healthcare landscape and market dynamics.
- Uncertainty about which indication would offer the best commercial potential for their drug candidate.
- Need for a compelling business case to present to potential Series A investors.
- Lack of in-depth US market data to support strategic decision-making.
The company needed a partner with deep expertise in the US healthcare system and the ability to conduct thorough market analysis to guide their indication selection and market entry strategy.
Delphi’s Approach
Delphi employed a comprehensive, data-driven approach to address our client’s challenges:
- US Healthcare Market Education: Delphi provided our client with in-depth education on the US healthcare system, including payer landscapes, reimbursement pathways, and regulatory considerations.
- Comparative Indication Analysis: Leveraging our extensive knowledge of the US market, Delphi conducted a high-level comparative analysis of multiple potential indications for the drug candidate, including Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Tobacco Use Disorder (TUD), and Anxiety Disorders (GAD/SAD).
- Data-Driven Insights: Delphi analyzed three key datasets covering Medicare, Medicaid, and a large commercial insurer with over 1 million lives to provide robust, quantitative insights into market opportunities and patient journeys.
- Strategic Presentations: Delphi developed two key presentations – a narrative deck and a quantitative deck – to clearly communicate their findings and recommendations to our client.
- Ongoing Support: Beyond the initial deliverables, Delphi provided continuous support, including a deep dive into selected indications and assistance during our client’s fundraising efforts.
- Market Entry Strategy: Based on their analysis, Delphi articulated potential market entry strategies, with a focus on two promising indications.
This approach allowed Delphi to provide our client with a comprehensive understanding of the US market landscape and data-backed recommendations for their product development and commercialization strategy.
Results and Impact
Delphi’s engagement with our client yielded several significant outcomes:
- Enhanced Market Understanding: Our client gained a comprehensive understanding of the US healthcare system, enabling more informed strategic decisions.
- Data-Driven Indication Selection: The quantitative analysis provided a clear rationale for prioritizing specific indications, particularly AUD and Smoking Cessation, based on market potential and feasibility.
- Improved Investor Positioning: Armed with Delphi’s analysis and recommendations, our client was better equipped to present a compelling business case to potential Series A investors.
- Refined Go-to-Market Strategy: The market entry strategies articulated by Delphi helped our client develop a more focused and achievable commercialization plan.
Accelerated Decision-Making: The comprehensive analysis and ongoing support from Delphi enabled our client to make faster, more confident decisions about their product development pathway.
Key Learnings
Several important insights emerged from this engagement:
- Market-Driven Development: The importance of aligning drug development with market needs and payer priorities in the US healthcare system became evident.
- Indication Flexibility: The analysis revealed the potential for a single psychedelic compound to address multiple indications, offering strategic flexibility in development and commercialization.
- Payer Landscape Complexity: The project underscored the intricate nature of the US payer system and the need for a nuanced approach to each payer segment.
- Patient Journey Focus: Understanding the patient journey for each indication proved crucial in identifying the most promising market opportunities.
- Data-Driven Decision Making: The power of comprehensive data analysis in guiding strategic decisions and convincing investors was clearly demonstrated.
- Ongoing Expert Support: The value of continuous expert guidance throughout the drug development and commercialization process was highlighted, particularly for companies entering new markets.
These learnings not only benefited our client but also enhanced Delphi’s expertise in guiding biotech companies through US market entry strategies for novel therapeutics.
Conclusion
This engagement showcased Delphi’s ability to provide comprehensive, data-driven guidance to biotech companies navigating the complex US healthcare landscape. By leveraging our deep understanding of the US market, robust data analysis capabilities, and strategic insight, we were able to help our European client make informed decisions about their novel psychedelic therapeutic development pathway and market entry strategy.
Our work not only provided our client with a clear direction for their drug candidate but also equipped them with the knowledge and tools necessary to present a compelling case to investors. This engagement underscored the critical importance of thorough market analysis and strategic planning in the early stages of drug development, particularly for companies entering the US market for the first time.
